Patient-reported outcomes with calcipotriol/betamethasone aerosol foam in patients with plaque psoriasis in Greece. Results from the CELSUS study.

Rigopoulos, D; Lazaridou, E; Papadavid, E; Georgiou, S; Chasapi, V; Sfaelos, K; Cheliotis, G; Ioannides, D

Rigopoulos, D; Lazaridou, E; Papadavid, E; Georgiou, S; Chasapi, V; Sfaelos, K; Cheliotis, G; Ioannides, D.

Afiliação

Rigopoulos D; 1st Department of Dermatology-Venereology, University of Athens, Athens, Greece.
Lazaridou E; 2nd Department of Dermatology-Venereology, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece.
Papadavid E; 2nd Department of Dermatology and Venereology, ATTIKON University Hospital, Athens, Greece.
Georgiou S; Department of Dermatology, Medical School, General University Hospital, University of Patras, Patras, Greece.
Chasapi V; Department of Dermatology and Venereology NHS, Andreas Syggros Hospital, Athens, Greece.
Sfaelos K; Dermatology, LEO Pharma Hellas, Athens, Greece.
Cheliotis G; Health Data Specialists S.A, Athens, Greece.
Ioannides D; First Department of Dermatology-Venereology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

J Eur Acad Dermatol Venereol ; 35(12): e931-e934, 2021 Dec.

Article em En | MEDLINE | ID: mdl-34374131

Assuntos

Fármacos Dermatológicos; Psoríase; Aerossóis; Betametasona; Calcitriol/análogos & derivados; Fármacos Dermatológicos/uso terapêutico; Combinação de Medicamentos; Grécia; Humanos; Medidas de Resultados Relatados pelo Paciente; Psoríase/tratamento farmacológico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Fármacos Dermatológicos Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google